Compare McDonald's Corp (MCD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs GeneDx Holdings Corp — how do they compare? McDonald's Corp trades at $235.7 (market cap $163.38B), while GeneDx Holdings Corp trades at $67.67 (market cap $2.04B). The key difference: McDonald's Corp is far larger — about 80.1× GeneDx Holdings Corp's market cap, and McDonald's Corp pays a 3.34% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold McDonald's Corp for 164 Days and GeneDx Holdings Corp for 19 Days on average.
| MCD | WGS | |
|---|---|---|
Market Cap | $163.38B | $2.04B |
Volume | 4,647,229 | 659,215 |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $167.51 |
52-Week Low | $230.88 | $34.51 |
Typical Hold Time | 164 Days | 19 Days |
Enterprise Value | $217.15B | $2.08B |
Dividend Yield | 3.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $236.9, up 1.91% for the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $26.89B and net income of $8.56B, supported by a 57.38% gross margin. Recent news highlights a new 'NEXT' growth strategy focusing on automation and menu innovation to counter competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $286.95 price target, but technical indicators and macroeconomic headwinds pose risks. Investment opportunity lies in McDonald's resilient franchise model and dividend yield, though inflation and execution of new initiatives are key watchpoints for shareholders.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
